Trade Summary

6 days ago, Hoitt Jason, serving as Chief Patient Officer at Stoke Therapeutics, Inc. (STOK), sold 3,712 shares at $32.14 per share, for a total transaction value of $119,311.00. Following this transaction, Hoitt Jason now holds 10,276 shares of STOK.

This sale represents a 27.00% decrease in Hoitt Jason's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, March 17, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, March 19, 2026, 2 days after the trade was made.

Stoke Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.